Syndax Pharmaceuticals (SNDX) Profit After Tax (2016 - 2020)
Historic Profit After Tax for Syndax Pharmaceuticals (SNDX) over the last 6 years, with Q4 2020 value amounting to -$20.4 million.
- Syndax Pharmaceuticals' Profit After Tax fell 4587.86% to -$20.4 million in Q4 2020 from the same period last year, while for Dec 2020 it was -$73.2 million, marking a year-over-year decrease of 3052.97%. This contributed to the annual value of -$318.8 million for FY2024, which is 5225.35% down from last year.
- Latest data reveals that Syndax Pharmaceuticals reported Profit After Tax of -$20.4 million as of Q4 2020, which was down 4587.86% from -$20.4 million recorded in Q3 2020.
- In the past 5 years, Syndax Pharmaceuticals' Profit After Tax registered a high of -$8.4 million during Q2 2016, and its lowest value of -$20.4 million during Q3 2020.
- Moreover, its 5-year median value for Profit After Tax was -$15.0 million (2016), whereas its average is -$15.4 million.
- Its Profit After Tax has fluctuated over the past 5 years, first tumbled by 10549.12% in 2016, then surged by 2627.07% in 2019.
- Syndax Pharmaceuticals' Profit After Tax (Quarter) stood at -$10.8 million in 2016, then tumbled by 76.64% to -$19.1 million in 2017, then grew by 1.4% to -$18.8 million in 2018, then rose by 25.68% to -$14.0 million in 2019, then tumbled by 45.88% to -$20.4 million in 2020.
- Its Profit After Tax stands at -$20.4 million for Q4 2020, versus -$20.4 million for Q3 2020 and -$17.1 million for Q2 2020.